Healthcare & Medical Devices Global On demand · 24-48h

Global Lower Limb Artery Interventional Devices Market Strategic Research Report

Global Lower Limb Artery Interventional Devices Market Strat…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Lower Limb Artery Interventional Devices Market
$4662025
15.1%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Balloon Angioplasty, Stenting, Endovascular Volume Reduction, Other

By Application: Iliac Artery, Femoral Artery, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Boston Scientific Corporation, Cordis Corporation, Abbott, W.L. Gore & Associates, Becton, BD, Medtronic, Cook Medical, Acotec Scientific, Cardio Flow, Zylox-Tonbridge Medical Technology, Zhejiang Barty Medical Technology, Shanghai Microport Endovascular Medtech(Group), Leo Medical, OrbusNeich Medical Group, Wei Qiang (Shanghai) Medical Technology, Philips

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 132 pages
Market size 2025
$466
Million USD
Forecast CAGR
15.1%
2025-2032
Forecast 2032
$1247.1
Projected
Regionen
5
Asia Pacific · Latin America · MEA · Europe · North America

Übersicht

Scope of the Report

The global Lower Limb Artery Interventional Devices market size is predicted to grow from US$ 466 million in 2025 to US$ 1,229 million in 2032; it is expected to grow at a CAGR of 15.1% from 2026 to 2032.

Lower extremity arterial disease refers to a disease in which localized stenosis or occlusion of lower extremity arteries causes ischemia of the body. Stenosis or occlusion of lower extremity arteries can cause symptoms such as intermittent claudication, cold skin in the legs or feet, chronic pain, and gangrene. The main cause of lower extremity arterial disease is atherosclerosis, and lesions related to atherosclerosis account for 90%-95% of all lesions. The 5-year mortality rate of patients with intermittent claudication is about 30%, while the 5-year mortality rate of patients with lower extremity ischemia with rest pain, ulcers, and gangrene is as high as 70%.

Global key Lower Limb Artery Interventional Devices players cover Boston Scientific Corporation, Cordis Corporation, Abbott, W.L. Gore & Associates, Becton, etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Lower Limb Artery Interventional Devices market?

What factors are driving Lower Limb Artery Interventional Devices market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Lower Limb Artery Interventional Devices market opportunities vary by end market size?

How does Lower Limb Artery Interventional Devices break out by Type, by Application?

This report presents a comprehensive overview of the global Lower Limb Artery Interventional Devices market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Balloon Angioplasty
  • Stenting
  • Endovascular Volume Reduction
  • Other

Segment by Application

  • Iliac Artery
  • Femoral Artery
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Lower Limb Artery Interventional Devices market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Iliac Artery, Femoral Artery, Other evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Lower Limb Artery Interventional Devices Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 15.1%
Regional growth momentum
Market share by segment
Key metrics
Base value
$466
2025
Forecast
$1247.1
2032
CAGR
15.1%
2025–2032
Regionen
5
global
Key companies
Boston Scientific CorporationCordis CorporationAbbottW.L. Gore & AssociatesBectonBDMedtronicCook Medical
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Balloon AngioplastyStentingEndovascular Volume ReductionOther
By Application
Iliac ArteryFemoral ArteryOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Balloon Angioplasty
  • 3.1.3 Stenting
  • 3.1.4 Endovascular Volume Reduction
  • 3.1.5 Other
  • 3.1.6 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Iliac Artery
  • 4.1.3 Femoral Artery
  • 4.1.4 Other
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Boston Scientific Corporation
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Cordis Corporation
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Abbott
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 W.L. Gore & Associates
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Becton
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 BD
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Medtronic
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Cook Medical
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Acotec Scientific
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Cardio Flow
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Zylox-Tonbridge Medical Technology
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Zhejiang Barty Medical Technology
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Shanghai Microport Endovascular Medtech(Group)
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Leo Medical
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 OrbusNeich Medical Group
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Wei Qiang (Shanghai) Medical Technology
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Philips
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the current global Lower Limb Artery Interventional Devices market size?
The global Lower Limb Artery Interventional Devices market is estimated at US$ 466 million in 2025 (base year) and is projected to reach US$ 1.23 billion by 2032.
What growth rate is expected for the Lower Limb Artery Interventional Devices market through 2032?
The market is expected to grow at a CAGR of 15.1% from 2026 to 2032, expanding from US$ 466 million in 2025 to US$ 1.23 billion in 2032, roughly 2.6 times its base-year value.
How is Lower Limb Artery Interventional Devices defined?
Lower extremity arterial disease refers to a disease in which localized stenosis or occlusion of lower extremity arteries causes ischemia of the body. Stenosis or occlusion of lower extremity arteries can cause symptoms such as intermittent claudication, cold skin in the legs or feet, chronic pain, and gangrene. The main cause of lower extremity arterial disease is atherosclerosis, and lesions related to atherosclerosis account for 90%-95% of all lesions.
How is the Lower Limb Artery Interventional Devices market segmented by type?
By type, the market is segmented into Balloon Angioplasty, Stenting, Endovascular Volume Reduction and Other.
What are the key applications of Lower Limb Artery Interventional Devices?
Key applications covered include Iliac Artery, Femoral Artery and Other.
Which companies are profiled in the Lower Limb Artery Interventional Devices market report?
Key players profiled include Boston Scientific Corporation, Cordis Corporation, Abbott, W.L. Gore & Associates, Becton, BD, Medtronic and Cook Medical, among 17 companies covered in total.
What geographies does the Lower Limb Artery Interventional Devices market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Lower Limb Artery Interventional Devices?
What factors are driving Lower Limb Artery Interventional Devices market growth, globally and by region?
Who should buy the Lower Limb Artery Interventional Devices market report?
The report is intended for manufacturers and solution providers, distributors and end users in Iliac Artery, Femoral Artery and Other, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Lower Limb Artery Interventional Devices market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3.500,00 $
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.